Therapeutic drug monitoring: Antiarrhythmic drugs

British Journal of Clinical Pharmacology, Supplement

Volumn 52, Issue SUPPL. 1, 2001, Pages

  Campbell, T J ^a   Williams, K M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiarrhythmic drugs; Therapeutic drug monitoring

Indexed keywords

EID: 0034838866     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2001.00768.x     Document Type: Review

References (162)

1. Goldberger BA, Jenkins AJ. Testing of abused drugs in urine by immunological techniques. AACC In-service Training Continuing Ed 1992; 13: 7-18.
2. Valdes R, Jortani SA, Gheorghiade M. Standards of laboratory practice: cardiac drug monitoring. Clin Chem 1998; 44: 1096-1109.
3. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Cardiovasc Pharmacol 1984; 24: 129-147.
4. Campbell TJ. Subclassification of class I antiarrhythmic drugs: Enhanced relevance after CAST. Cardiovasc Drugs Ther 1992; 6: 519-528.
5. Rosen MR, Schwartz PJ. The Sicilian Gambit. A new approach to the classification of antiarhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851.
6. Campbell TJ. Antiarrhythmic drugs. In Manual of Coronary Care ed Thompson P. Churchill Livingstone, London, 1997; 225-244.
7. Grant AO. Mechanisms of action of antiarrhythmic drugs: From ion channel blockage to arrhythmia termination. Pacing Clin Electrophysiol 1997; 20: 432-444.
8. Katz AM. Cardiac ion channels. N Engl J Med 1993; 328: 1244-1251.
9. Velebit V, Podrid PJ, Lown B, Cohen BH, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982; 65: 886-894.
10. Ruskin JN, McGovern B, Garan H, Dimarco JP, Kelly E. Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med 1983; 309: 1302-1306.
11. Hoffman BF, Dangman JH. The role of antiarrhythmic drugs in sudden cardiac death. J Am Coll Cardiol 1986; 8: 104A-109A.
12. Rae AP, Kay HR, Horowitz LN, Spielman SR, Greenspan AM. Pro arrhythmic effects of antiarhythmic drugs with malignant ventricular arrhythmias evaluated by electrophsiologic testing. J Am Coll Cardiol 1988; 12: 131-139.
13. The Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
14. Cardiac Arrhythmia Suppression Trial II. Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-233.
15. IMPACT Research Group. International mexiletine and placebo antiarrhythmic coronary trial I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984; 4: 1148.
16. Morganroth J. Early and late proarrhythmia from antiarrhythmic drug therapy. Cardiovasc Drugs Ther 1992; 6: 11.
17. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990; 82: 1106-1116.
18. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation 1991; 84: 1977-1983.
19. Teo KK, Yusuf S, Fuberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993; 270: 1589-1595.
20. Wyse KR, Ye V, Campbell TJ. Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: Implications for proarrhythmia due to triggered activity. J Cardiovasc Pharmacol 1993; 21: 316-322.
21. Campbell TJ. Pro-arrhythmic action of antiarrhythmic drugs: A review. Aust NZJ Med 1990; 20: 275-282.
22. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115-172.
23. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Circ Res 1985; 56: 857-867.
24. Dessertenne F. La tachycardie ventriculaire a deux foyers oppose variables. Arch Mai Coeur 1966; 59: 263-272.
25. Taggart W, Holyoak W. Steady-state bioavailability of two sustained-release quinidine preparations. Clin Ther 1983; 5: 357-361.
26. Huynh-ngoc T, Sirois G. Comparison of two spectroflurometric procedures for quinidine determination in biological fluids. J Pharm Sci 1977; 66: 591-592.
27. Guentert TW, Upton RA, Holford NH, Riegelman S. Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods. J Pharmacokinet Biopharmaceut 1979; 7: 303-311.
28. Smith GH, Levy RH. Serum quinidine determination: comparison of mass-spectrometric and extraction-fluorescence methods. Drug Clin Pharmacy 1982; 16: 693-695.
29. MacKichan JJ, Shields BJ. Specific high performance liquid chromatograqphic determination of quinidine in serum, blood, and urine. Ther Drug Monit 1987; 9: 104-112.
30. Ahokas JT, Davies C, Ravenscroft PJ. Simultaneous analysis of disopyramide and quinidine in plasma by high-performance liquid chromatography. J Chromatogr 1980; 183: 65-71.
31. Williams KM. Molecular asymmetry and its pharmacological consequences. Adv Pharmacol 1991; 22: 57-135.
32. Kavanagh KM, Wyse G, Mitchell LB, Gilhooly T, Gillis AM, Duff HJ. Contribution of quinidine metabolites to electrophysiologic responses in human subjects. Clin Pharmacol Ther 1989; 46: 352-358.
33. TDx/TDx, FLx Systems Assays Manual. Abbott Laboratories, Abbott Park, Illinois, 1994.
34. Sokolow M, Ball RE. Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration. Circulation 1956; 14: 568-583.
35. Gerhardt RE, Knouss RF, Thyrum PT, et al. Quinidine excretion in aciduria and alkaluria. Ann Intern Med 1969; 71: 927.
36. Leahey EB, Reiffel JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA 1978; 240: 533.
37. Bussey HI. The influence of quinidine and other agents on digitalis glycosides. Am Heart J 1982; 104: 289.
38. Bussey HI. Update on the influence of quinidine and other agents on digitalis glycosides. Am Heart J 1984; 107: 143.
39. Hinderling PH, Garrett ER. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokin Biopharmaceut 1976; 4: 199-230,.
40. Baines MW, Davies JE, Keilett DN, Munt PL. Some pharmacological effects of disopyramide and a metabolite. J Int Med Res 1976; 4(Suppl 1): 5-7,.
41. Zema M. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation. Ther Drug Monit 1984; 6: 192-198.
42. Le Corre P, Gibassier D, Sado P, Le Verge R. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. Drug Metah Dispos 1988; 16: 858-864.
43. Giacomini KM, Nelson WL, Pershe RA, Valdivieso L, Turner-Tamiyasu Blaschke TF. In vivo interaction of the enantiomers of disopyramide in human subjects. J Pharmacokinet Biopharmaceut 1986; 14: 335-338.
44. Vurke TR Jr, Nelson WL. Resolution, absolute configuration, and antiarrhythmic properties of the enantiomers of disopyramide. J Med Chem 1980; 23: 1044-1048.
45. Le Corre P, Gibassier D, Sado P, Le Verge R. Simultaneous assay of disopyramide and monodesisopropyldisopyramide enantiomers in biological samples by liquid chromatography. J Chromatogr 1988; 424: 424-429.
46. Giacomini KM, Cox BM, Blaschke TF. Comparative anticholinergic potencies of R- and S-disopyramide in longitudinal muscle strips from guinea pig ileum. Life Sci 1980; 27: 1191-1197.
47. Niarchos AP. Disopyramide: serum level and arrhythmia conversion. Am Heart J 1976; 92: 57-64.
48. Meffm PJ, Robert EW, Winkle RA, et al. Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokin Biopharmaceut 1979; 7: 29-46.
49. David BM, Madsen BW, Ilett KF. Plasma binding of disopyramide. Br J Clin Pharmacol 1980; 9: 614-618.
50. Thibonniew M, Holford NHG, Upton RA, Blume CD, Williams RL. Pharmacokinetic - Pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. J Pharmacokin Biopharmaceut 1984; 12: 559-573.
51. Duff HJ, Mitchell LB, Nath CF, Manyari DE, Baynton R, Wyse DG Concentration-response relationships of disopyramide in patients with ventricular tachycardia. Clin Pharmacol Ther 1989; 45: 542-547.
52. Routledge PA, Stargel WW, Wagner GS, Shand DG. Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Int Med 1980; 93: 701-704.
53. Cunningham JL, Shen DD, Shudo I, et al. The effect of urine pH and plasma protein binding on renal clearance of disopyramide. Clin Pharmacokin 1977; 2: 373-383.
54. Darim A, Nissen C, Azarnoff DL. Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm 1982; 10: 465.
55. Giardina EGV, Dreyfuss J, Bigger JT, et al. Metabolism of procainamide in normal and cardiac subjects. Clin Pharmacol Ther 1976; 19: 339-351.
56. Roden DM, Reele SB, Higgins SB, et al. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetyl-procainamide in human subjects: comparison with procainamide. Am J Cardiol 1980; 46: 463-468.
57. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 1975; 17: 722-730
58. Braden GL, Fitzgibbons JP, Germain MJ, Ledewitz HM. Hemoperfusion for treatment of N-acetylprocainamide intoxication. Ann Intern Med 1986; 105: 64-65.
59. Kastrup J, Petersen P, Dejgard A, Angelo HR, Hilsted J. Intravenous lidocaine infusion - a new treatment of chronic painful diabetic neuropathy? Pain 1987; 28: 69-75.
60. Swerdlow M. The use of local anaesthetics for the relief of chronic pain. Pain Clinic 1988; 2: 3-6.
61. Glazer S, Portenoy RK Systemic local anesthetics in pain control. J Pain Sytnpt 1991; 6: 30-39.
62. Stenson RE, Constantino RT, Harrison DC. Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 1971; 43: 205-211.
63. Blumer J, Strong JM, Atkinson AJ. The convulsant potency of lidocaine and its JV-dealkylated metabolites. J Pharmacol Exp Ther 1978; 180: 31-36.
64. Chen Y, Potter JM. Fluorescence polarization immunoassay and HPLC assays compared for measuring monoethylglycinexylidide in liver-transplant patients. Clin Chem 1992; 38: 2426-2430.
65. Thomson AH, Kelman AW, deVane PJ, Hillis WS, Whiting B. Changes in lignocaine disposition during long-term infusion in patients with acute ventricular arrrythmias. Ther Drug Monit 1987; 9: 283-291.
66. Halkin H, Meffm P, Melmon KL, Rowland M. Influence of congestive heart failure on blood levels of lidocaine and its active mono-de-ethylated metabolite. Clin Pharmacol Ther 1975; 17: 669-676.
67. Prescott LF, Pottage A, Clements JA. Absorption, distribution and elimination of mexiletine. Postgrad Med J 1977; 53: 50-55.
68. Haselbarth V, Doevendans J, Wolf M. Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 1981; 29: 729-736.
69. Campbell NPS, Pantridge JF, Adgey AAJ. Long-term oral antiarrhythmic therapy with mexiletine. Br Heart J 1978; 40: 796-801.
70. Pringle T, Fox J, McNeill JA, et al. Dose independent pharmacokinetics of mexiletine in healthy volunteers. Br J Clin Pharmacol 1986; 21: 319-321.
71. Jarzabek JI. Analyte of the month. AACC In-Service Training Continuing Ed, 1991, 12, 3-4.
72. Grech-Belanger O, Turgeon J, Gilbert M. Steroselective disposition of mexiletine in man. Br J Clin Pharmacol 1986; 21: 481-487.
73. Igwemezie L, Kerr CR, McErlane KM. The pharmacokinetics of the enantiomers of mexiletine in humans. Xenobiotica 1989; 19: 677-682.
74. Turgeon J, Uprichard ACG, Belanger PM, Harron DQG, Grech-Belanger O. Resolution and electrophysiological effects of mexiletine enantiomers. J Pharm Pharmacol 1991; 43: 630-635.
75. McErlane KM, Igwemezie L. Stereoselective analysis of the enantiomers of mexiletine by high-performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man.J Chromatogr 1987; 415: 335-346.
76. Hodges M, Haugland JM, Conard GJ, Carlson GL, Frost JW, Ober RE. Human plasma pharmacokinetics of flecainide acetate (R-818), a new antiarrhythmic, following single oral and intravenous doses. Clin Pharmacol Ther 1979; 25: 218.
77. Hodges M, Haugland JM, Granrud G, et al. Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic drug. Circulation 1982; 65: 879-885.
78. Lui HK, Lee G, Dietrich P, et al. Flecainide-induced QT prolongation and ventricular tachycardia. Am Heart J 1982; 103: 567-569.
79. Spivack C, Gottlieb S, Miura DS, Somberg JC. Flecainide toxicity. Am J Cardiol 1984; 53: 329-330.
80. Guehler J, Gornick CC, Tobler HG, et al. Electrophysiologic effects of flecainide acetate and its major metabolites in the canine heart. Am J Cardiol 1985; 55: 807-812.
81. Johnson JD, Carlson GL, Fox JM, Miller AM, Chang. SF, Conard GJ. Quantitation of flecainide acetate, a new antiarrhythmic agent, in biological fluids by gas chromatography with electron-capture detection. J Pharm Sci 1984; 73: 1469-1471.
82. Ray J. Flecainide: What are we measuring? Ther Drug Monit 1991; 13: 86.
83. Lie-A, Huen L, Stuurman RM, Ijdenberg FN, Dingma JH, Meijer DKF. High-performance liquid chromatographic assay of flecainide and its enantiomers in serum. Ther Drug Monit 1989; 11: 708-711.
84. Alessi-Severini S, Jamali F, Pasutto FM, Courts RT, Gulamhusein S. High-Performance liquid chromatographic determination of the enantiomers of flecainide in human plasma and urine. J Pharm Sci 1990; 79: 257-260.
85. Turgeon J, Kroemer HK, Prakash C, Blair IA. Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with florescence detection. J Pharm Sci 1990; 79: 91-95.
86. Kroemer HK, Turgeon J, Parker RA, Roden DM. Flecainide enantiomers: Disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther 1989; 46: 584-590.
87. Lie-A-, Huen L, Van den Akker J, Den Hertog A, Meijer DKF. The action of flecainide acetate and its enantiomers on mammalian non-myelinated nerve fibres. Pharm Wkblt (Sci) 1989; 11: 92-94.
88. Smallwood JK, Robertson DW, Steinberg MI. Electrophysiological effects of flecainide enantiomers in canine Purkinje fibres. Naunyn-Schmiedeherg's Arch Pharmacol 1989; 339: 625-629.
89. Gross AS, Mikus G, Fisher C, Hertrampf R, Gundert-Remy U, Eichelbaum M. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol 1989; 28: 555-556.
90. Brigerdotter UM, Wong W, Turgeon J, Roden DM. Stereoselective genetically - determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol 1992; 33: 275-280.
91. Mikus G, Gross AS, Beckmann J, Gertrampf R, Gundert-Remy U, Eichelbaum M. The influence of the sparteine/ debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 1989; 45: 562-567.
92. Dukes ID, Vaughan Williams EM. The multiple modes of action of propafenone. Eur Heart J 1984; 5: 115-125.
93. Somberg JC, Tepper D, Landau S. Propafenone: a new antiarrhythmic agent. Am Heart J 1988; 115: 1274-1279.
94. Hollman M, Hege H, Brode E, et al. Pharmacokinetic and metabolic studies of propafenone in volunteers. In Cardiac arrhythmias eds Schlepper M, Molsson B. Proc First Int Rythmonorm Congress. Springer, Berlin Heidelberg New York, 1983; 125-132.
95. Connolly SJ, Kates RE, Lebsack CS, et al. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 1983; 52: 1208-1213.
96. Salerno DM, Granrud G, Sharkey P, et al. A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. Am J Cardiol 1984; 53: 77-83.
97. Somberg JC. Clinical use of Class Ic antiarrhythmic drugs. In Antiarrhythmic Drugs ed Vaughan Williams EM, Campbell TJ. Springer-Verlag, Berlin, 1989; 235-279.
98. Hiji JT, Duff JH, Burgess ED. Clinical pharmacokinetics of propafenone. Clin Pharmacokin, 1991, 21, 1-10.
99. Siddoway LA, Roden DM, Woosley RL. Clinical pharmacology of propafenone. Pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol 1984; 54: 9D-12D.
100. Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmocokinetic consequences. Circulation 1987; 75: 785-791.
101. Stoschietzky K, Klein W, Stark G, et al. Different stereoselective effects of R- and S-propafenone: Clinical pharmacology, electrophysiologic and radioligand binding studies. Clin Pharmacol Ther 1990; 47: 740-744.
102. Koytchev R, Aiken RG, Mayer O, Bohm R, Ellrich A, Waldner-Kolblin RG. The bioequivalence of two oral propafenone preparations. Arzneimittel Forsch 1995; 45: 542-545.
103. Oti-Amoako K, Vozeh S, Ha Huy-Riem Follath F. The relative potency of major metabolites and enantiomers of propafenone in an experimental reperfusion arrhythmia model. J Cardiovasc Pharmacol 1990; 15: 75-81.
104. Kroemer HK, Fromm MF, Buhl K, Terefe H, Blaschke G, Eichelbaum M. An enantiomer - enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation 1994; 89: 2396-2400.
105. Siddoway LA, McAlliser CB, Want T, et al. Polymorphic oxidative metabolism of propafenone in man. Circulation 1983; 68(Suppl): (III): 64-66.
106. Haefeli EW, Vozeh S, Ha HR, Fallath F. Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther 1990; 48: 245-254.
107. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993; 14 (Supp F): 18-25.
108. Campbell TJ. Beta-blockers for ventricular arrhythmia: Have we underestimated their value? Aust N ZJ Med 1996; 26: 689-696.
109. Nademanee K, Field G, Hendrickson J, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985; 72: 555-564.
110. Cobbe SM. Sotalol. In Antiarrhythmic drugs eds Vaughan Williams EM, Campbell TJ. Berlin: Springer-Verlag. 1989; 365-387.
111. Campbell TJ. Class III antiarrhythmic action: the way forward. Med J Aust 1993; 158: 732-733.
112. Soyka L, Witz C, Spangenbert R. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990; 65: 74A-81A.
113. Neuvonen P, Elonen E, Tarssanen L. Sotalol intoxication, two patients with concentration-effect relationships. Acta Pharmacol Toxicol 1979; 45: 52-57.
114. Boutagy J, Shenfield GM. Simplified procedure for the determination of sotalol in plasma by high-performance liquid chromatography. J Chromatogr 1991; 565: 523-528.
115. Gluth WP, Sorgel F, Gluth B, Braun J, Geldmacher von Mallinckrodt M. Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography. Arzneimittel Forsch 1988; 38: 408-411.
116. Barek MJ, Vekshteyn M, Boarman MP, Gallo DG. Liquid chromatographic determination of sotalol in plasma and urine employing solid-phase extraction and fluorescence detection. J Chromatogr 1987; 421: 309-318.
117. Karkkainen S. High-performance liquid chromatographic determination of sotalol in biological fluids. J Chromatogr 1984; 336: 313-319.
118. Fiset C, Philippon F, Gilbert M, Turgeon J. Stereoselective disposition of ( + )-sotalol at steady-state conditions. Br J Clin Pharmacol 1993; 36: 75-77.
119. Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, Ghevmol G The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. Eur J Clin Pharmacol 1990; 38: 579-582.
120. Somani P, Watson DL. Antiarrhythmic activity of the dextro- and levo-rotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl) methanesulphonamide. J Pharmacol Exp Ther 1968; 164: 317-325.
121. Singh BN, Sarma JSM. Amiodarone and amiodarone derivatives. In Cardiovascular Pharmacology and Therapeutics. eds Singh BN Dzau VJ Vanhoutte PIM. Woosley RL New York: Churchill Livingstone. 1994; 689-710.
122. Bauman JL, Berk SI, Hariman RJ, et al. Amiodarone for sustained ventricular tachycardia: efficacy, safety and factors influencing long-term outcome. Am Heart J 1987; 114: 436-444.
123. Pallandi RT, Campbell TJ. Resting and rate-dependent depression of Vmax of guinea-pig ventricular action potentials by amiodarone and desethyl-amiodarone. Br J Pharmacol 1987; 92: 97-103.
124. Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840-847.
125. Mitchell LB, Wyse G, Gillis AM, Duff HJ. Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. Circulation 1989; 80: 34-42.
126. Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Int Med 1984; 101: 462-469.
127. Counihan PJ, McKenna WJ. Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy. J Clin Pharm 1989; 29: 436-438.
128. Moysey JO, Jaggarao NSV, Grundy EN, et al. Amiodarone increases plasma digoxin concentration. Br Med J 1981; 282: 272-275.
129. Weir SJ, Ueda CT. Rapid liquid chromatographic assay for the determination of amiodarone and its N-deethyl metabolite in plasma, urine and bile.J Pharm Sci 1985; 74: 460-465.
130. Plomp TA, Engels M, Robles Medina EO, Maes RA. Simultaneous determination of amiodarone and its major metabolite desethylamiodarone in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr 1983; 273: 379-392.
131. Kannan R, Miller S, Perez V, Singh BN. Sensitive method for the measurement of amiodarone and desethylamiodarone in serum and tissue and its application to disposition studies. J Chromatogr 1987; 385: 225-232.
132. Pollak PT. A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Ther Drug Monit 1996; 18: 168-178.
133. Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interactions: Clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4: 111-116.
134. Denster PE, White NW Jr, Hanson CD. Pharmacokinetic evaluation of the digoxin - amiodarone interaction. J Am Coll Cardiol 1985; 5: 108-112.
135. Serlin MJ, Sibeon RG, Green GJ. Dangers of amiodarone and anticoagulant treatment. Br Med J 1981; 283: 57-58.
136. Pexid Product Summary for Physicians. Cincinnati, Ohio, Merrel Dow Pharmaceuticals Inc. 1982.
137. Lockhart JDF, Masheter HC. Report of a multicentre monitored release study of perhexiline maleate in the prevention of angina pectoris. Br J Clin Pract 1976; 30: 172.
138. Horowitz JD, Morris PM, Drummer O, Goble AJ, Louis WJ. Saturable metabolism of perhexiline maleate: Correlations with long term toxicity. Am J Cardiol 1981; 47: 399.
139. Singlas E, Goufet MAS, Imon P. Pharmacokinetics of perhexiline maleate in angina patients with and without peripheral neuropathy. Eur J Clin Pharmacol 1978; 14: 195-201.
140. Laplane D, Bousser MG, Bouche P, Touboul PJ. Peripheral neuropathies caused by perhexiline maleate. In Perhexiline maleate. Proceedings of a Symposium. Amsterdam, Excerpta Medica. 1978; pp. 89-96.
141. Vaughan Williams EM. Antiarrhythmic action and the puzzle of perhexiline. Academic Press, London, 1980.
142. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52: 273-280.
143. Horowitz JK, Sia STB, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris - correlations with pharmacokinetics. Int J Cardiol 1986; 13: 219-229.
144. Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-1270.
145. Horowitz JD, Morris PM, Drummer OH, Goble AJ, Louis WJ. High pressure liquid chromatographic assay of perhexiline maleate in plasma. J Pharmacol Sci 1981; 70: 320-322.
146. Amoh AG, Gould BJ, Parke DV. Single-dose pharmacokinetics of perhexiline administered orally to humans. J Chromatogr 1984; 305: 401-409.
147. Cooper RG, Harper G, Price AH, Evans DA, Lockhart JD. Simultaneous determination of perhexiline and its monohydroxy metabolites in biological fluids by gas chromatography - electron-capture detection. J Chromatogr 1986; 381: 305-314.
148. Gould BJ, Amoah AGB, Parke DV. Stereoselective pharmacokinetics of perhixiline. Xenohiotica 1986; 16: 491-502.
149. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982; 284: 295-299.
150. Siebert W. Perhexiline - stable plasma concentrations with formulation change. Aust NZJ Med 1996; 26: 707-708.
151. Morris RG, Frewin DB, Taylor WB, Glistak Ml, Lehmann DR. The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays. Eur J Clin Pharmacol 1988; 34: 233-239.
152. Natowicz M, Shaw L. Digoxin assay anomalies due to digoxin-specific fab immunotherapy. Ann Pharmacother 1991; 25: 739-741.
153. Kampa IS. The effect of digibind on various digoxin immunoassays. AACC In-Service Training Continuing Ed 1993; 14: 183-186.
154. Miller JJ, Straub RW Jr, Valdes R Jr Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS: 180. Ther Drug Monit 1996; 18: 65-72.
155. Goto A, Yamada K, Yagi N, Yoshioka M, Sugimoto T. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992; 44: 377-399.
156. Loucari-Yiannakou E, Yiannakou L, Souvatzooglou A, Diamandis EP. Radioimmunoassay of digoxin in serum using monoclonal antibodies and assessment of interference by digoxin-like immunoreactive substances. Ther Drug Monit 1990; 12: 195-200.
157. Gault H, Vasdev S, Vlasses P, Longerich L, Dawe M. Interpretation of serum digoxin values in renal failure. Clin Pharmacol Ther 1986; 39: 530-536.
158. Ray JE, Crisan D, Howrie D. Digoxin-like immunoreactivity in serum from neonates and infants reduced by centrifugal ultrafiltration and fluorescence polarization immunoassay. Clin Chem 1991; 37: 94-98.
159. Woodcock BG, Rietbrock N. Digitalis - quinidine interactions. Trends Pharmacol Sci 1997; 3: 118-122.
160. Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metah Dispos 1996; 24: 142-147.
161. Charuk JH, Loo TW, Clarke DM, Reithmeier RA. Interaction of rat kidney P-glycoprotein with a urinary component and various drugs including cyclosporin A. Am J Physiol 1994; 266: F 66-F 75.
162. Hori R, Okamuri N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993; 266: 1620-1625.